No black box warning on record for Zolgensma

As of the latest FDA labeling reviewed, Zolgensma (ONASEMNOGENE ABEPARVOVEC-XIOI) does not carry a black box warning. Standard warnings and precautions still apply — see the full Zolgensma medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Systemic Immune Response: Administer ZOLGENSMA to patients who are clinically stable in their overall baseline health status (e.g., hydration and nutritional status, absence of infection) prior to infusion. ( 5.2 ) Thrombocytopenia: Monitor platelet counts before ZOLGENSMA infusion, and at least weekly for the first month and then every other week for the second and thir

No black box warning on record for Zolgensma

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Systemic Immune Response: Administer ZOLGENSMA to patients who are clinically stable in their overall baseline health status (e.g., hydration and nutritional status, absence of infection) prior to infusion. ( 5.2 ) Thrombocytopenia: Monitor platelet counts before ZOLGENSMA infusion, and at least weekly for the first month and then every other week for the second and thir

Zolgensma Black Box Warning

No black box warning on record for Zolgensma

Other warnings & precautions

Zolgensma Black Box Warning

No black box warning on record for Zolgensma

Other warnings & precautions